

Supplemental Table 3. Clinical Characteristics of patients imaged with [¹⁸F]DASA-23

Patient	Diagnosis	Molecular Characteristics	Time between diagnosis and [¹⁸ F]DASA-23 PET	Medications at [¹⁸ F]DASA-23 PET scan	Time between surgery/biopsy and [¹⁸ F]DASA-23 PET	Additional notes
IC-1	WHO grade IV recurrent glioblastoma	IDH1 wt, MGMT methylated	-4 months	Famotidine (20mg), citalopram (20mg), gabapentin (1200 mg),#Norco 5-325, levetiracetam (2000mg) Post therapy scan after administration of bevacizumab (683 mg) and temozolomide 150mg/m ² 5 days per 28 day cycle	+2.5 months	Patient was previously receiving an experimental treatment BPM31510 (NCT03020602), tumor progression was identified ~2 weeks prior to [¹⁸ F]DASA-23 PET
IC-2	WHO grade IV newly diagnosed glioblastoma	IDH1 wt, MGMT unmethylated	-3 months	Dexamethasone (1mg), ondansetron (8mg), rabeprazole (20mg), temozolomide (250mg), bevacizumab (463mg)	-3 months	
IC-3	WHO Grade IV Diffuse Midline Glioma, H3 K27M-mutant	IDH1 wt	-12 months	Ondansetron (8mg), bevacizumab (348mg)	-12 months	Clinically stable for ~5 months at time of [¹⁸ F]DASA-23 PET
IC-4	WHO grade III recurrent anaplastic astrocytoma	IDH mutant, ATRX mutation	-7 months	Levetiracetam (1000mg), ondansetron (8mg), temozolomide(100mg), bevacizumab (625mg)	-7 months	